Based on the above, we sought to determine whether the reductions in vascular permeability achieved by anti-CCL2/12 antibodies were due to functional changes of the endothelial barrier, or could also be attributed to structural changes induced by our treatment to the pleural tumor neovasculature. Here, CCL2 is linked to pleural neoplasm.